Comparing the efficacy of Yashtimadhu Ghrita anal infiltration and Diltiazem topical application in the management of chronic anal fissure An Open label randomized controlled trial

CCRAS0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年5月29日

研究概览

暂无简介。

•1. Patients with co-morbidities such as fistula in ano, haemorrhoids, perianal abscess, clinically evident fecal incontinence, anal stenosis/fibrosis
•2. Patients with inflammatory bowel disease, tuberculosis, diabetes mellitus, anemia, malnourishment caused by systemic diseases, malignancy, HIV, STDs, hepatitis B
•3. Patients with uncontrolled hypertension, clinically significant renal disease, hepatic disease, cardiovascular disease, psychiatric disease
•4. Fissure associated with abscess, drug-induced fissure or fissure resulting from external trauma
•5. Fissure located at lateral locations and multiple fissures
•6. Patients on medications hampering wound healing (corticosteroids, NSAIDs, anti-convulsants, anticoagulants, immunosuppressive agents etc.)
•7. Patients using oral calcium channel blockers
•8. Patients with frequent h/o headache
•9. Active substance abuse
•10. Known hypersensitivity to either of the trial interventions
•11. Pregnant and lactating women
•12.Patients who have been using either of the trial interventions prior to 30 days of randomization

发起方

CCRAS